Company Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally.
Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection.
The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia.
Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
| Country | United States |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 56 |
| CEO | Krisztina Zsebo |
Contact Details
Address: 2155 Park Boulevard Palo Alto, California 94306 United States | |
| Phone | 650-279-9845 |
Stock Details
| Ticker Symbol | EIGRQ |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| CIK Code | 0001305253 |
| CUSIP Number | 15117E107 |
| ISIN Number | US28249U1051 |
| Employer ID | 36-1004130 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. David Apelian M.B.A., M.D., Ph.D. | Chief Executive Officer and Director |
| Dr. Jeffrey S. Glenn M.D., Ph.D. | Scientific Founder and Independent Director |
| William G. Kaichoff CPA | Chief Financial Officer and Principal Financial and Accounting Officer |
| Christopher A. Kurtz | Chief Technical Officer |
| James Vollins J.D. | General Counsel, Chief Compliance Officer and Corporate Secretary |
| Dr. Colin Hislop M.D., MBBS | Senior Vice President of Clinical and Development Operations |
| Dr. Colleen Craig M.D. | Senior Vice President of Metabolic Diseases |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2024 | 25-NSE | Filing |
| Apr 8, 2024 | 10-K | Annual Report |
| Apr 3, 2024 | 8-K | Current Report |
| Apr 1, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Apr 1, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 1, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 1, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 1, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 1, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 1, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |